Oncology and Hematology

Episodes 49-64 of 77

• 

  RestartResume

  Managing Adverse Events Associated With ICI Combinations in Patients With Unresectable HCC

  RestartResume

  Managing Adverse Events Associated With ICI Combinations in Patients With Unresectable HCC

  MinuteCE®

  Managing Adverse Events Associated With ICI Combinations in Patients With Unresectable HCC

  1.00 program credit

  • 

    

    Aiwu Ruth He, MD, PhD

  1.00 program credit

• 

  RestartResume

  Pivotal Data Supporting First-Line Durvalumab/Tremelimumab in Unresectable HCC

  RestartResume

  Pivotal Data Supporting First-Line Durvalumab/Tremelimumab in Unresectable HCC

  MinuteCE®

  Pivotal Data Supporting First-Line Durvalumab/Tremelimumab in Unresectable HCC

  1.00 program credit

  • 

    

    Ghassan K. Abou-Alfa, MD

  1.00 program credit

• 

  RestartResume

  Pivotal Data Supporting First-Line Atezolizumab/Bevacizumab in Unresectable HCC

  RestartResume

  Pivotal Data Supporting First-Line Atezolizumab/Bevacizumab in Unresectable HCC

  MinuteCE®

  Pivotal Data Supporting First-Line Atezolizumab/Bevacizumab in Unresectable HCC

  1.00 program credit

  • 

    

    Aiwu Ruth He, MD, PhD

  1.00 program credit

• 

  RestartResume

  Emerging First-Line ICI Combination Regimens in Patients With Unresectable HCC

  RestartResume

  Emerging First-Line ICI Combination Regimens in Patients With Unresectable HCC

  MinuteCE®

  Emerging First-Line ICI Combination Regimens in Patients With Unresectable HCC

  1.00 program credit

  • 

    

    Ghassan K. Abou-Alfa, MD

  1.00 program credit

• 

  RestartResume

  Case Consult: Treatment Options for an Unresectable HCC Patient Who Has Esophageal Varices

  RestartResume

  Case Consult: Treatment Options for an Unresectable HCC Patient Who Has Esophageal Varices

  MinuteCE®

  Case Consult: Treatment Options for an Unresectable HCC Patient Who Has Esophageal Varices

  1.00 program credit

  • 

    

    Aiwu Ruth He, MD, PhD

  1.00 program credit

• 

  MinuteCE®

  Unresectable Hepatocellular Carcinoma: Selecting the Optimal First-Line ICI Combination

  1.00 credit 10 episodes

  • 

    

    Aiwu Ruth He, MD, PhD

  • 

    

    Ghassan K. Abou-Alfa, MD

  1.00 credit 10 episodes

• 

  RestartResume

  Empowering Treatment Choice: The Essential Role of Shared Decision-Making in Unresectable HCC

  RestartResume

  Empowering Treatment Choice: The Essential Role of Shared Decision-Making in Unresectable HCC

  MinuteCE®

  Empowering Treatment Choice: The Essential Role of Shared Decision-Making in Unresectable HCC

  1.00 program credit

  • 

    

    Ghassan K. Abou-Alfa, MD

  • 

    

    Aiwu Ruth He, MD, PhD

  1.00 program credit

• 

  RestartResume

  Enhancing Outcomes in Unresectable HCC Through Integrated Multidisciplinary Care Models

  RestartResume

  Enhancing Outcomes in Unresectable HCC Through Integrated Multidisciplinary Care Models

  MinuteCE®

  Enhancing Outcomes in Unresectable HCC Through Integrated Multidisciplinary Care Models

  1.00 program credit

  • 

    

    Ghassan K. Abou-Alfa, MD

  • 

    

    Aiwu Ruth He, MD, PhD

  1.00 program credit

• 

  RestartResume

  Current Unmet Needs in the Field of Unresectable HCC

  RestartResume

  Current Unmet Needs in the Field of Unresectable HCC

  MinuteCE®

  Current Unmet Needs in the Field of Unresectable HCC

  1.00 program credit

  • 

    

    Ghassan K. Abou-Alfa, MD

  • 

    

    Aiwu Ruth He, MD, PhD

  1.00 program credit

• 

  RestartResume

  You Don’t Know WHIM Syndrome (A Chronic Neutropenic Disorder)

  RestartResume

  You Don’t Know WHIM Syndrome (A Chronic Neutropenic Disorder)

  MinuteCE®

  You Don’t Know WHIM Syndrome (A Chronic Neutropenic Disorder)

  1.00 program credit

  • 

    

    Peter E. Newburger, MD

  1.00 program credit

• 

  MinuteCE®

  WHIM Syndrome (A Chronic Neutropenic Disorder): Uncouple the Complex for HCPs and Patients

  1.00 credit 7 episodes

  • 

    

    Jolan Walter, MD, PHD

  • 

    

    Teresa K. Tarrant, MD

  • 

    

    Peter E. Newburger, MD

  • 

    

    Jacob R. Bledsoe, MD

  1.00 credit 7 episodes

• 

  RestartResume

  WHIM Syndrome and CXCR4 Variants: New Insights into Cellular Changes That Can Impact Patient Treatment Plans

  RestartResume

  WHIM Syndrome and CXCR4 Variants: New Insights into Cellular Changes That Can Impact Patient Treatment Plans

  MinuteCE®

  WHIM Syndrome and CXCR4 Variants: New Insights into Cellular Changes That Can Impact Patient Treatment Plans

  1.00 program credit

  • 

    

    Jacob R. Bledsoe, MD

  1.00 program credit

• 

  RestartResume

  WHIM Syndrome: A Misguided Immune System!

  RestartResume

  WHIM Syndrome: A Misguided Immune System!

  MinuteCE®

  WHIM Syndrome: A Misguided Immune System!

  1.00 program credit

  • 

    

    Peter E. Newburger, MD

  1.00 program credit

• 

  RestartResume

  WHIM Syndrome Treatment: We Can Do Better!

  RestartResume

  WHIM Syndrome Treatment: We Can Do Better!

  MinuteCE®

  WHIM Syndrome Treatment: We Can Do Better!

  1.00 program credit

  • 

    

    Jolan Walter, MD, PHD

  1.00 program credit

• 

  RestartResume

  WHIM Syndrome: A Chronic Neutropenic Disorder

  RestartResume

  WHIM Syndrome: A Chronic Neutropenic Disorder

  MinuteCE®

  WHIM Syndrome: A Chronic Neutropenic Disorder

  1.00 program credit

  • 

    

    Peter E. Newburger, MD

  1.00 program credit

• 

  RestartResume

  Goals of Therapy for WHIM Syndrome (a Chronic Neutropenic Disorder)

  RestartResume

  Goals of Therapy for WHIM Syndrome (a Chronic Neutropenic Disorder)

  MinuteCE®

  Goals of Therapy for WHIM Syndrome (a Chronic Neutropenic Disorder)

  1.00 program credit

  • 

    

    Teresa K. Tarrant, MD

  1.00 program credit